Gene&i: A tool for supporting your genetic testing conversations
In this article
Gene&i is a suite of educational resources that will support you in your first clinical discussions about genetic testing with your patients living with breast cancer.
Through providing you and your team with a clear and accessible conversation aid, patients can be more informed about genetic testing and those who are eligible can consider getting a test as early as possible.
Gene&i covers the basics on genetics, what genetic testing is, why it’s important, and addresses the most common concerns expressed by patients.
Clinicial guidelines recommend genetic testing for those with triple-negative breast cancer, recurrent or metastatic breast cancer, high-risk HR+/HER2- breast cancer, male patients with breast cancer, and individuals with a family history of certain types of cancer.1–3
Unfortunately, not all eligible patients are being tested — over 60% of patients with advanced HR+/HER2- breast cancer (the largest breast cancer subtype) may still be missing out.4,5
Gene&i is here to ensure you, your patients, and your team have everything they need to navigate and encourage the important discussion of genetic testing.
This Gene&i conversation aid helps you discuss genetic testing with your patients, they can use it to make notes, bring it to future appointments or share it with loved ones.
These short, animated videos give your patients the opportunity to recap your in-clinic discussions. They can be viewed at home via the QR codes in the Gene&i conversation aid or be shown in-clinic to help patients further understand genetic testing.
Join G as she gives you a quick glimpse into how Gene&i is by your side as you learn how genetic testing is done, and why genetic testing can be one of the important first steps in your breast cancer journey.
In this informative video we break down the basics of DNA and dive into the science behind genetic mutations. Discover how these mutations can play a pivotal role in breast cancer care and what they may mean for you.
Let’s explore the importance of genetic testing for breast cancer. We’ll go over why the results from a genetic test may offer valuable insights that you and your healthcare team can use to guide the management of your breast cancer.
What does risk really mean? In this video we’ll help you make sense of risk in the context of genetic testing and your breast cancer. We'll navigate through the diverse definitions of “risk”, delve into the crucial characteristics that may define your risk status and how best to manage it.
In this video, we’ll be answering some of the most common questions about genetic testing, including what to expect after receiving a test, how long genetic testing can take and how your genetic information will be used and protected.
HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NCCN, National Comprehensive Cancer Network® (NCCN®).
References:
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessments: Breast, Ovarian, Pancreatic and Prostate V.2.2025. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 8, 2024. To view the most recent and complete version of the guideline, go to NCCN.org.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.6.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 12, 2024. To view the most recent and complete version of the guideline, go to NCCN.org.
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12): 1475–1495. Referenced from ESMO Metastatic Breast Cancer Living Guidelines, v1.1 May 2023.
- Mahtani R, Niyazov A, Lewis K, et al. Adv Ther. 2023;40(1):331–348.
- Orranita-Borunda E, Anchondo-Nuñez P, Acuña-Aguilar LE, et al. Subtypes of Breast Cancer. Chapter 3. Breast cancer. [online]. Brisbane (AU): Exon Publications; August 2022. https://www.ncbi.nlm.nih.gov/books/NBK583808/.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims
any responsibility for their application or use in any way.
This website has been developed and funded by AZ and is intended for non-US, non-UK healthcare professionals only.